Özet:

Aim: We aimed to find the incidence of hypophoshatemia and to investigate predictive factors for the development of hypophospahtemia in patients with chronic kidney disease (CKD) treated with intravenous ferric carboxymaltose (FCM). Methods: In our single center retrospective study, we included 43 adult patients who were given FCM therapy after nefrology clinical admission. Thirty-three non-dialysis CKD patients constituded the CKD group. The control group consisted of 11 patients with the diagnosis of iron deficiency anemia and normal renal function. Patients with missing data on serum phosphorus level before and after treatment were excluded. Results: The average age of CKD group was 68.8±10.2 years (69% female). The average serum creatine level and estimated glomerular filtration rate were 2.3±1.1 mg/dL and 29.7±17.6 mL/min/1.73m2, respectively. After the first week following FCM treatment, five of 11 patients in the control group (44.5%) and three of 32 patients in the CKD group (9.4%) developed hypophosphatemia (p=0.008). On linear regression analysis, it was found that the baseline phosphorus level was the single predictor of hypophosphatemia (p=0.006). Conclusion: Our study demonstrated that the incidence of hypophosphatemia associated with FCM treatment in CKD patients was compatible with the rates in the literature. Clinics should be careful in FCM treatment especially in patients with low baseline phosphorus level.